| ¿µ¹® | Down syndrome | ÇÑ±Û | ´Ù¿îÁõÈıº |
|---|---|---|---|
| ¼³¸í | »ç¶÷ÀÇ 46°³ ¿°»öü Áß Á¦ 21¹ø ¿°»öüÀÇ ¼ö°¡ 1°³ ´õ ¸¹¾ÆÁö¹Ç·Î½á ³ªÅ¸³ª´Â º´ÀÌ´Ù. ȯÀÚÀÇ »ý±è»õ°¡ ¸¶Ä¡ ¸ù°í »ç¶÷°ú ´à¾Ò´Ù ÇÏ¿© ÀÏ¸í ¸ù°íÁõ(mongolism)À̶ó°í ÇÏ¿´À¸³ª À߸øµÈ À̸§ÀÌ´Ù. ÀÌ º´Àº ¹Ýµå½Ã 21¹ø ¿°»öü°¡ 3°³°¡ µÇ´Â °æ¿ìÀ̿ܿ¡µµ 21¹ø ¿°»öüÀÇ ÀϺκÐÀÌ ´Ù¸¥ ¿°»öüÀÇ ÀϺκаú ±³È¯ÀÌ µÇ´Â translocationÇü µîÀÇ ´Ù¸¥ ¿°»öüÀ̻󿡼µµ º¼ ¼ö°¡ ÀÖ´Ù. ¹ß»ý ºóµµ´Â Ãâ»ý¾Æ 700~1000¸íÁß 1¸í ²Ã·Î ³ªÅ¸³ª¸ç, ¿°»öü ÀÌ»óº´ Áß¿¡ °¡Àå ¸¹Àº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ÀÌ º´ÀÇ ¹ß»ýºóµµ´Â »ê¸ðÀÇ Ãâ»ê¿¬·É°ú ¹ÐÁ¢ÇÑ °ü°è°¡ ÀÖ¾î, 35¼¼ ÀÌÈİ¡ µÇ¸é ±âÇÏ ±Þ¼öÀûÀ¸·Î ÀÌ ÁúȯÀÚÀÇ Ãâ»ê¼ö°¡ Áõ°¡ÇÑ´Ù. ÀϹÝÀûÀ¸·Î ÀÌ Áúȯ¿¡ ÀÖ¾î¼ ¾à 3ºÐÀÇ 1Àº ¸ðÄ£ÀÇ Ãâ»ê¿¬·É¿¡ ÀÇÁ¸ÇÏÁö ¾Ê°í, ³ª¸ÓÁö ¾à 3ºÐÀÇ 2´Â ¸ðÄ£ÀÇ ¿¬·É°ú Á÷Á¢ °ü·ÃÀÌ ÀÖ´Â °ÍÀ¸·Î º¸°í ÀÖ´Ù. Áø´ÜÀº Ư¡ÀûÀÎ »ý±è»õ, Áï ¸ù°í »ç¶÷°°ÀÌ ´«²¿¸®°¡ À§·Î Ä¡ÄÑÁ® ÀÖ°í ´«°ÅÇ®ÀÌ µÎ²¨¿ì¸ç ÄàµîÀÌ ³·Àº Ư¡ÀûÀÎ ¾ó±¼ ¸ð½À, ¶ÇÇÑ ±ÙÀ°ÀÇ ±äÀåµµ°¡ ÀúÇϵǰí Á¥À» ºü´Â Èû°ú ¿ïÀ½ ¼Ò¸®°¡ ¾àÇÏ¸ç ¼Õ¹Ù´ÚÀÇ Á¿츦 °¡¸£´Â ÇÑÁÙÀÇ ¼Õ±Ý(¿ø¼þÀÌ¿Í °°Àº ÇüÅÂÀÌ´Ù) µîÀÇ Æ¯Â¡ÀûÀÎ ¼Ò°ß¿¡ ÀÇÇØ º¸Á¶Áø´ÜÀ» Çϰí ÃÖÁ¾ÀûÀ¸·Î ¿°»öü ºÐ¼®¿¡ ÀÇÇØ È®ÁøÀ» ÇÑ´Ù. ÀÌ ´Ù¿îÁõÈıºÀÇ È¯ÀÚ´Â ´ë°³ Áö´ÉÀÌ ÀúÇϵǾî ÀÖ°í, ¿©·¯ °¡Áö Á¾·ùÀÇ ¼±Ãµ¼º ½ÉÀå±âÇüÀ» ¸¹ÀÌ µ¿¹ÝÇϰí ÀÖ´Ù. |
||
| ¿µ¹® | dumping syndrome | ÇÑ±Û | ´ýÇÎÁõÈıº |
|---|---|---|---|
| ¼³¸í | ºÎºÐÀû À§ÀýÁ¦¼ú ¶Ç´Â À§ºóâÀÚ¿¬°á¼úÀ» ¹ÞÀº ȯÀÚ¿¡°Ô¼ À½½ÄÀ» ¸ÔÀº ÈÄ¿¡ ÀϾ´Â ÁõÈıºÀÌ´Ù. ¸íÄ¡ ºÎºÐÀÇ ÆØ¸¸°¨°ú ¾Ð¹Ú°¨-±¸¿ª-±¸Åä µîÀÇ º¹ºÎÁõ»ó ¿Ü¿¡ Å»·Â°¨-Çö±âÁõ-¹ßÇÑ-°¡½¿¶ê µî ¼øÈ¯Àå¾Ö Áõ»óÀÌ µû¸¥´Ù. ±×·± Áõ»óÀº ¼·ÃëÇÑ À½½Ä¹°ÀÌ À§¿¡¼ ÀÛÀºÃ¢ÀÚ·Î Ãß¶ôÇÏµí ¹èÃâµÊÀ¸·Î½á À½½Ä¹°ÀÇ ¹«°Ô·Î ÀÎÇØ ¼ÒȰüÀÌ ¾Æ·¡ÂÊÀ¸·Î ÃÄÁ®µç´Ù. ÀÛÀºÃ¢ÀÚº®ÀÌ ±Þ°ÝÇÏ°Ô ´Ã¾î³ªµç°¡, ÈÇÐÀû ÀÚ±ØÀ¸·Î ÀÎÇÑ ÀÛÀºÃ¢ÀÚº®ÀÇ ÀÚÀ²½Å°æ¹Ý»ç, ÀÛÀºÃ¢ÀÚº®ÀÇ »ïÅõ¾Ð¿¡ ÀÇÇØ ¼ÒȰüÀ¸·Î ¼öºÐÀÌ ±Þ¼ÓÈ÷ ´ë·® À̵¿ÇÏ¿© ¼øÈ¯µÇ´Â Ç÷¾×ÀÇ ¾çÀÌ °¨¼ÒÇÏ¿© ÀϾÙ. ÁÖ·Î ½Ä»ç¿ä¹ýÀ¸·Î Ä¡·áÇÏ¿©, ¾à¹°¿ä¹ýÀ¸·Î´Â ¾ÆÆ®·ÎÇÉ-Çí»ç¸ÞÅä´½-Æä³ë¹Ù¸£ºñÅ»-ź»ê¼ö¼Ò³ªÆ®·ýÀÇ »ç¿ë ¹× Æ÷µµ´çÁֻ絵 È¿°ú°¡ ÀÖ´Ù. ¼ö¼ú¿ä¹ýÀº ºô·Î½º(Billroth) Á¦1¹ýÀ¸·ÎÀÇ º¯È¯, ´ë¿ëÀ§ÀÇ Á¦ÀÛ µîÀÌ ÀÖÀ¸³ª È®½ÇÇÑ °ÍÀº ¾Æ´Ï´Ù. |
||
| ¿µ¹® | Raynaud syndrome | ÇÑ±Û | ·¹À̳ëÁõÈıº |
|---|---|---|---|
| ¼³¸í | »çÁöÀÇ ´ëĪÀû û»öÁõÀ» Ư¡À¸·Î ÇÏ´Â Áõ»óÀ¸·Î¼ ¼Õ°¡¶ô-¼Õ¸ñ µîÀÇ ÇǺΰ¡ Áö¼ÓÀûÀ¸·Î û»ö°ú Àû»öÀ¸·Î º¯Çϰí, ¼Õ°¡¶ôÀÇ ´ë·® ¶¡³²°ú ³Ã°¢À» ¼ö¹ÝÇÑ´Ù. |
||
| ¿µ¹® | battered child syndrome | ÇÑ±Û | ¸Å¸Â´Â ¾ÆÀÌ ÁõÈıº |
|---|---|---|---|
| ¼³¸í | ¿µÀ¯¾Æ³ª ¼Ò¾Æ°¡ ºÎ¸ð µîÀÇ º¸À°ÀÚ³ª ÇüÁ¦ÀڸŷκÎÅÍ ¹Ýº¹Çؼ ½ÅüÀûÀÎ Çд븦 ¹Þ¾Æ ¹ß»ýÇÏ´Â °¢Á¾ Áõ»çÀÇ ÃÑĪÀÌ´Ù. 1962³â ÄÍÇÁ(Kempe)¿¡ ÀÇÇØ ¸í¸íµÇ¾ú´Ù. »óó¸¦ ¹ÞÀº ½Ã±â°¡ ¼·Î Â÷À̰¡ ÀÖ´Â ¿Ü»óÀÌ ¸ö Àüü ¿©·¯ °÷¿¡¼ °üÂûµÇ´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ÇǺÎÀÇ ¼Õ»ó°ú ¾ó·èÃâÇ÷, °æÁú¸·ÇÏ Ç÷Á¾, °ñÀý µîÀÌ ¸¹°í ±Ø´ÜÀûÀÎ °æ¿ì´Â ¿µ±¸Àû ³ú¼Õ»ó°ú Á×À½¿¡ À̸£´Â °æ¿ìµµ ÀÖ´Ù. Çд뵿±â´Â ÇÇÇØÀÚ ÀÔÀå¿¡¼´Â À°Ã¼Àû-Á¤½ÅÀû ¹ßÀ°ºÎÀü, ½ÖµÕÀÌ, ±âÇü, ¹ãÁß¿¡ ¿ì´Â °Í, ¾ß´¢Áõ, Àå³, ¹ÝÇ×Àû ŵµ µîÀÌ ÀÖÀ¸¸ç °¡ÇØÀÚ ÀÔÀå¿¡¼´Â º¸À°ÀÚÀÇ ¾ÆÀÌ¿¡ ´ëÇÑ ¾ÖÁ¤°áÇ̰ú °úÀ× ±â´ë, À°¾Æ¿¡ ´ëÇÑ ¹«Áö, ÇüÁ¦Àڸſ¡ ´ëÇÑ ½Ã»ù, Á¤½Åº´, ½Å°æÁõ, Áö´ÉÀúÇÏ, ¾ËÄÚ¿Ã Áßµ¶ µîÀÌ ÀÖ°í, ¶Ç »ýȰȯ°æÀÇ ÀÔÀå¿¡¼´Â ºó°ï, ºÎºÎ ºÒÈ, ÇÙ°¡Á·ÀÌ¸é¼ »çȸÀûÀ¸·Î °í¸³µÈ °¡Á¤ µîÀ» µé ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | severe acute respiratory syndrome(SARS) | ÇÑ±Û | »ç½º |
|---|---|---|---|
| ¼³¸í | Áß±¹ ±¤µ¿ Áö¿ª¿¡¼ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼º È£Èí±â ÁúȯÀ¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â ȯÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â ħ¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀÇ È£Èí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. ħ¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇÏ´Ù´Â ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù. |
||
| PS | pacemaker syndrome; paired stimulation; paradoxical sleep; paraspinal; parasympathetic; Parkinson sy... |
|---|---|
| CS | calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ... |
| PCS | palliative care service; Patient Care System; patterns of care study; pelvic congestion syndrome; ph... |
| MAP | malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ... |
| MBP | major basic protein; maltose-binding protein; management by policy; mannose-binding protein; mean bl... |
| acyl-(acyl-carrier-protein)-phospholipid acyltransferase | <enzyme> Catalyses the formation of phosphatidylethanolamine from acyl-acyl carrier protein and 2-acyl-sn-glycero-3-phosphoethanolamine Registry number: EC 2.3.1.40 Synonym: 2-acyl-gpe acyltransferase, 2-acylglycerophosphoethanolamine acyltransferase (26 Jun 1999) |
|---|---|
| acyl-(acyl-carrier-protein)-UDP-N-acetylglucosamine acyltransferase | <enzyme> E coli enzyme involved in lipid a biosynthesis; uses beta-hydroxymyristoyl-acyl carrier protein to form udp-3-monoacyl-n-acetylglucosamine; amino acid sequence given in second source Registry number: EC 2.3.1.129 Synonym: udp-aguatransferase, lpxa protein, udp-n-acetylglucosamine-3-acyltransferase, udp-n-acetylglucosamine 3-o-acyltransferase, udp-3-o-(r-3-hydroxymyristoyl)glucosamine-n-acyltransferase, lpxd protein, fira gene product, fira protein (26 Jun 1999) |
| acyl carrier protein | <protein> A small (77 peptides long) protein which binds six other enzymes involved in fatty acid synthesis. It was first isolated in E. Coli bacteria. (09 Oct 1997) |
| acyl carrier protein acylase | <enzyme> From E coli Registry number: EC 2.3.1.- Synonym: acp acylase (26 Jun 1999) |
| acyl protein synthetase | <enzyme> Component of the fatty acid reductase complex of luminescent bacteria Registry number: EC 2.3.1.- Synonym: luxe gene product, fatty acyl-protein synthetase (26 Jun 1999) |
| AKT1 protein kinase | <enzyme> Human homolog of v-akt oncogene product Registry number: EC 2.7.10.- Synonym: akt1 protein, human (26 Jun 1999) |
| AMP-activated protein kinase kinase | <enzyme> An endogenous kinase kinase; reactivates the inactive form of AMP-activated protein kinase (AMP-pk); phosphorylates the 63-kD subunit of AMP-pk Registry number: EC 2.7.1.- Synonym: AMP-pk reactivator, hmg CoA reductase kinase kinase (26 Jun 1999) |
| amyloid beta-protein | A 4 kD protein, 39-43 amino acids long, expressed by a gene located on chromosome 21. It is the major protein subunit of the vascular and plaque amyloid filaments in individuals with alzheimer's disease and in aged individuals with trisomy 21 (down syndrome). The protein is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue. (12 Dec 1998) |
| amyloid beta-protein precursor | A precursor to the amyloid-beta protein (beta/a4). Alterations in the expression of the amyloid beta-protein precursor (abpp) gene, located on chromosome 21, plays a role in the development of the neuropathology common to both alzheimer disease and down syndrome. Abpp is associated with the extensive extracellular matrix secreted by neuronal cells. Upon cleavage, this precursor produces three proteins of varying amino acid lengths: 695, 751, and 770. The beta/a4 (695 amino acids) or beta-amyloid protein is the principal component of the extracellular amyloid in senile plaques found in alzheimer disease, down syndrome and, to a limited extent, in normal aging. (12 Dec 1998) |
| amyloid precursor protein | <protein> Individuals with Alzheimer's disease are characterised by extensive accumulation of amyloid in the brain, referred to as senile plaques. These consist of a core of amyloid fibrils surrounded by dystrophic neurites. The principal component of the amyloid fibrils is B/A4, a peptide derived from the larger APP. The specific role of amyloid protein is unclear but it is thought that amyloid deposits may cause neurons to degenerate. Amyloid deposits also occur in brains of older Down's Syndrome patients. (04 May 1997) |
| amyloid protein | Glycoprotein deposited extracellularly in tissues in amyloidosis. The glycoprotein may either derive from light chain of immunoglobulin (AIO (amyloid of immune origin): 5-18 kD glycoprotein, product of a single clone of plasma cells, the N terminal part of lambda or kappa light chain) or, in what used to be referred to as AUO, amyloid of unknown origin, from serum amyloid A (SAA), one of the acute phase proteins that increases many fold in inflammation. The polypeptides are organised as a _ pleated sheet making the material rather inert and insoluble. Minor protein components are also found. Should be distinguished from _ amyloid deposited in the brain and that is derived from amyloid precursor protein (see amyloidogenic glycoprotein. (18 Nov 1997) |
| amyloid protein aa | A nonimmunoglobulin amyloid isolated from amyloid fibrils deposited in amyloidosis secondary to chronic inflammatory diseases such as rheumatoid arthritis. Antisera to amyloid protein aa have been used to detect a related serum protein saa. (12 Dec 1998) |
| amyloid protein saa | A serum protein believed to be a circulating precursor to amyloid protein aa. It is present in low concentrations in normal sera, but found in much higher concentrations in sera of older persons and in patients with amyloidosis or with diseases known to predispose to amyloidosis. Very high levels of this protein have been reported during acute inflammatory episodes. Antisera to amyloid protein aa cross-react with protein saa. (12 Dec 1998) |
| androgen binding protein | A protein secreted by testicular Sertoli cells along with inhibin and mullerian inhibiting substance. Androgen binding protein probably maintains a high concentration of androgen in the seminiferous tubules. (05 Mar 2000) |
| animal protein factor | <biochemistry> Member of the water soluble B vitamin group, important in the proper function of the nervous system and important in proper carbohydrate, protein and fat metabolism. (27 Sep 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|